Journal
JOURNAL OF CLINICAL MICROBIOLOGY
Volume 59, Issue 9, Pages -Publisher
AMER SOC MICROBIOLOGY
DOI: 10.1128/JCM.01094-21
Keywords
-
Categories
Ask authors/readers for more resources
Stenotrophomonas maltophilia is inherently resistant to several antibiotics, making treatment challenging. Automated susceptibility testing for S. maltophilia is limited by the performance of commercial test systems, requiring practical implementation and risk mitigation strategies.
Stenotrophomonas maltophilia is intrinsically resistant to many beta-lactam antibiotics, including carbapenems, and is resistant to aminoglycosides, which limits the therapeutic repertoire for managing S. maltophilia infections. Additionally, employing automated in vitro susceptibility testing of S. maltophilia is challenging because commercial test systems' performance is limited (A. Khan, C. A. Arias, A. Abbott, J. Dien Bard, et al., J Clin Microbiol 59:e00654-21, 2021, https://doi.org/10.1128/JCM.00654-21). This commentary will briefly discuss the opportunity to use automated commercial susceptibility testing systems with S. maltophilia, with a focus on how to implement their use practically while mitigating risk of error.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available